α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives
Expert Reviews in Molecular Medicine · 2026
DOI: 10.1017/erm.2026.10037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, 2026. Verfasst von Imogen J H Grimwade und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience, Surgery & Trauma, The Blizard Institute, https://ror.org/026zzn846Faculty of Medicine and Dentistry, Queen Mary University o…. Hauptthemen laut MEDLINE: alpha-Synuclein, Lewy Body Disease, Lewy Bodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Research UK, Barts Charity.
Abstract (Originalsprache)
Lewy bodies (LBs) are the main pathological feature of the neurodegenerative diseases Parkinson’s disease and Dementia with LBs. Since their discovery over 100 years ago, it is only in the last three decades, that, a wealth of genetic, pathological and pre-clinical evidence puts the spotlight on accumulated α-Synuclein (α-Syn) as the main component of LBs and implicated as a driver of these diseases. This has catapulted clinical trials for these diseases focussing on strategies to remove, reduce, disaggregate and prevent propagation of α-Syn. Advances in technical approaches have started to build a bigger picture of the complexity of LBs extending beyond α-Syn. There is still much to be learned about the processes underlying the formation and structure of LBs and their relationship to neurodegeneration. This will likely impact upon how we target these diseases therapeutically, diagnose them and build clinical trials. Here, we will discuss LBs in the context of α-Syn and other features, modelling strategies and how to direct research moving forwards in order to get clinical results. A more complete understanding of LBs and potential novel targets that drive their formation will likely lead to better outcomes in LB diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Neuroscience, Surgery & Trauma, The Blizard Institute, https://ror.org/026zzn846Faculty of Medicine and Dentistry, Queen Mary University of London, UK.
- https://ror.org/03yghzc09University of Exeter, Exeter, UK.
- Independent Researcher, UK.
- Centre for Preventive Neurology, https://ror.org/026zzn846Faculty of Medicine and Dentistry, Queen Mary University of London, UK.
- Queen Square Brain Bank for Neurological Disorders, https://ror.org/0370htr03UCL Queen Square Institute of Neurology, London, UK.
ORCID-Profile: Imogen J H Grimwade, Grey Enticknap, Cara Louise Croft
Förderung
- Alzheimer's Research UK
- Barts Charity
Zitieren
APA
Grimwade, I. J. H., Enticknap, G., De Pablo Fernandez, E., & Croft, C. L. (2026). α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives. Expert Reviews in Molecular Medicine. https://doi.org/10.1017/erm.2026.10037
Vancouver
Grimwade IJH, Enticknap G, De Pablo Fernandez E, Croft CL. α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives. Expert Reviews in Molecular Medicine. 2026. doi:10.1017/erm.2026.10037
BibTeX
@article{Grimwade2026,
author = {Grimwade, Imogen J H and Enticknap, Grey and De Pablo Fernandez, Eduardo and Croft, Cara Louise},
title = {α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
doi = {10.1017/erm.2026.10037}
}
EUVIMED